title: [The use of acatinol in the treatment of stable patients with schizophrenia with predominance of behaviour disorganization and subcatatonic features].
abstract: Our study was based on the hypothesis that a non competitive antagonist of NMDA receptors can improve clinical effects of antipsychotic therapy in a subgroup of patients with schizophrenia with clinical signs of glutamatergic hyperfunction such as catatonic symptoms and disorganization. The study design was open and non-comparative. The duration of the study for each patient was 6 months, the target dosage of acatinol was 20 mg. Forty stable patients with schizophrenia with predominance of signs of disorganization and subcatatonic symptoms were included. The following instruments were used: PANSS, NSA, CGI, BACS, UKU. Adding of acatinol to the antipsychotic treatment improved clinical symptoms, cognitive functioning and social functioning and decreased the number of side effects. The drug was well-tolerated.
authors.forename: M A
authors.initials: MA
authors.lastname: Morozova
authors.forename: G E
authors.initials: GE
authors.lastname: Rupchev
authors.forename: I G
authors.initials: IG
authors.lastname: Kozhekin
authors.forename: T B
authors.initials: TB
authors.lastname: Arsenieva
authors.forename: R A
authors.initials: RA
authors.lastname: Cheremin
authors.forename: V N
authors.initials: VN
authors.lastname: Yachmenev
authors.forename: E Yu
authors.initials: EY
authors.lastname: Onegina
authors.forename: A K
authors.initials: AK
authors.lastname: Shvedova
authors.forename: A G
authors.initials: AG
authors.lastname: Beniashvili
authors.forename: D S
authors.initials: DS
authors.lastname: Burminsky
authors.forename: T A
authors.initials: TA
authors.lastname: Lepilkina
authors.forename: S S
authors.initials: SS
authors.lastname: Potanin
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012560:Schizophrenia, Catatonic / Q000175:diagnosis / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D015259:Dopamine Agents; D008559:Memantine